ERBB2 and neoplasm: Roelof (70) indicated that the combination of human epidermal growth factor receptor 2 (HER2) and cluster of differentiation 44 (CD44) into 18F-FDG PET-based clinico-radiomic feature (Geary’s C measure and long-run low gray-level emphasis) prediction models improved nCRT response prediction in EC through assessing the expression of HER2 and CD44 by immunohistochemistry in pre-treatment tumor biopsies of 96 subjects.